Abstract
The UK Lung Cancer Screening trial (UKLS) aims to evaluate low-dose computed tomography (LDCT) lung cancer population screening in the United Kingdom. In UKLS, a large population sample ages 50 to 75 years is approached with a questionnaire to determine lung cancer risk. Those with an estimated risk of at least 5% of developing lung cancer in the next 5 years (using the Liverpool Lung project risk model) are invited to participate in the trial. Here, we present demographic, risk, and response rate data from the first 88,897 individuals approached. Of note, 23,794 individuals (26.8% of all approached) responded positively to the initial questionnaire; 12% of these were high risk. Higher socioeconomic status correlated positively with response, but inversely with risk (P < 0.001). The 50- to 55-year age group was least likely to participate, and at lowest cancer risk. Only 5% of clinic attendees were ages ≤60 years (compared with 47% of all 88,897 approached); this has implications for cost effectiveness. Among positive responders, there were more ex-smokers than expected from population figures (40% vs. 33%), and fewer current smokers (14% vs. 17.5%). Of note, 32.7% of current smokers and 18.4% of ex-smokers were designated as high risk. Overall, 1,452 of 23,794 positive responders (6.1%) were deemed high risk and attended a recruitment clinic. UKLS is the first LDCT population screening trial, selecting high-risk subjects using a validated individual risk prediction model. (i) better recruitment from ex- rather than current smokers, (ii) few clinic attendees ages early 50s, and (iii) representative number of socioeconomically deprived people recruited, despite lower response rates.
Highlights
Lung cancer kills more people in the United Kingdom than any other cancer
UK Lung Cancer Screening trial (UKLS) is similar in methodology to NELSON, and this will allow a combined analysis of results to increase the statistical power of both trials
The results suggest a fairly sharp increase at 58 years of age in the percentage of positive responders at high Liverpool Lung Project (LLP) risk, from around 1% to 4.3%
Summary
Lung cancer kills more people in the United Kingdom than any other cancer. It accounts for over 20% of all deaths from malignancy, and 6% of total deaths; there were moreAuthors' Affiliations: 1University of Liverpool; 2Liverpool Heart and Chest Hospital, Liverpool; 3University of Nottingham, Nottingham; 4St. Lung cancer kills more people in the United Kingdom than any other cancer. It accounts for over 20% of all deaths from malignancy, and 6% of total deaths; there were more. Authors' Affiliations: 1University of Liverpool; 2Liverpool Heart and Chest Hospital, Liverpool; 3University of Nottingham, Nottingham; 4St. Georges Hospital; 5Medical Research Council; 6Wolfson Institute; 7Royal Brompton Hospital; 8Barts and London University, London; 9Cardiff University School of Medicine, Cardiff; 10University of Cambridge; 11Papworth Hospital, Cambridge; 12Aberdeen Royal Infirmary, Aberdeen; and 13University of Edinburgh, Edinburgh, United Kingdom. Note: Supplementary data for this article are available at Cancer Prevention Research Online (http://cancerprevres.aacrjournals.org/). S.W. Duffy and J.K. Field are joint senior authors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.